Multi-site/Other

Short Name	Comments	Type	Investigator	Contact
SHUB	**The Spectrum Health Universal Biorepository Provides a Robust, Diverse Offering of High Quality Research and Potential Diagnostic Samples Associated with Relevant De-identified Clinical Data to Investigators**	Biobanking	**SHORE**: Dr. Sandra Cottingham	**Spectrum Health Biorepository** david.chesla@spectrumhealth.org (616) 267-2629
AGCT1531	**A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients With Germ Cell Tumors**	Treatment	**CRCWM** Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
AGCT1532	**Phase 3 Accelerated BEP: A Randomised Phase 3 Trial of Accelerated Versus Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours**	Treatment	**CRCWM** Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
S1609 DART	**Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors**	Treatment	**CRCWM** Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
A221701	**Alliance A221701, Phase III placebo-controlled trial to evaluate dexamethasone use for everolimus-induced oral stomatitis: prevention versus early treatment approaches: MIST (My Individualized Stomatitis Treatment)**	Symptom Management	**CRCWM** Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
A231601CD	**Improving Surgical Care and Outcomes in Older Cancer Patients through Implementation of An Efficient Pre-Surgical Toolkit (OPTI-surg)**	Cancer Care Delivery	**CRCWM** Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org

A221602	**Olanzapine with or without Fosaprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV) in Patients Receiving Highly Emetogenic Chemotherapy (HEC): A Phase III Randomized, Double-Blind, Placebo-Controlled Trial**	Symptom Management	**CRCWM** Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
DCP-001	**Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)**	Screening	**CRCWM** Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
S1714	**A Prospective Observational Cohort Study to Develop A Predictive Model of Taxane-Induced Peripheral Neuropathy in Cancer Patients**	Quality of Life	**CRCWM** Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
URCC 18007	**Randomized Placebo-Controlled Trial of Bupropion for Cancer-Related Fatigue**	Symptom Management	**CRCWM** Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
WF-10217	**Work Ability in Young Adult Survivors (WAYS)**	Behavioral	**CRCWM** Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
EAZ171	**Prospective validation trial of taxane therapy (docetaxel or weekly paclitaxel) and risk of chemotherapy-induced peripheral neuropathy in African American Women**	Supportive Care	**CRCWM** Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org

A231602CD	**Assessing Financial Difficulty in Patients with Blood Cancers**	Economics of Care	**CRCWM** Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
EAY131-MATCH Screening Trial	**Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma**	Molecular Profiling	**CRCWM** Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
ASCO TAPUR	**Targeted Agent and Profiling Utilization Registry Study: All Drugs Provided**	Molecular Profiling	**CRCWM** Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
NCI PDM 9846	**Patient-derived Models Tissue Procurement Protocol for the National Cancer Institute**	Biobanking	**CRCWM** Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
ACCRU 2018-01	**Blood Sample Collection to Evaluate Biomarkers in Subjects with Untreated Solid Tumors**	Other	**CRCWM** Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
APEC1621	**Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients with Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Trial)**	Treatment	**CRCWM** Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
2020-285	**NCI COVID-19 In Cancer Patients Study (N-CCaPS): A Longitudinal Natural History Study**	Molecular Profiling	**CRCWM** Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org

Exact Sciences	**Blood Sample Collection to Evaluate Biomarkers in Subjects with Untreated Solid Tumors from Twelve Primary Cancer Diagnoses: Breast, Lung, Colorectal, Prostate, Bladder, Uterine, Kidney, Renal, Pelvis, Pancreatic, Liver, Stomach, Ovarian, and Esophageal Cancer**	Biobanking	**CHCWM** Physician Investigators	CHCWM (616) 954-9800 www.chcwm.com
STMW 2020.03	**A Phase 1b, First-in-Human, Dose Escalation and Expansion Study of XMT-1536 In Patients with Solid Tumors Likely to Express NaPi2b**	Treatment	**CHCWM** Physician Investigators	CHCWM (616) 954-9800 www.chcwm.com
ALX148 (Alexo)	***AT1488001:*** **Phase I, Dose Escalation Study of ALX148 in Patients with Advanced Solid Tumors or Lymphoma Examining Safety, Pharmacokinetics and Tolerability. Now in Combination Phase II with Pembrolizumab, Rituximab, and Trastuzumab**	Treatment	**START Midwest** Investigators	START Midwest (616) 954-5554
AVID-100	***AVID100-01:*** **A Phase IA/IIA Cohort Dose Escalation Trial to Determine the Safety, Tolerance, Maximum Tolerated Dose, and Preliminary Antineoplastic Activity of AVID100, an Anti-Human Epidermal Growth Factor Receptor (EGFR) Monoclonal Antibody Linked to the Maytansinoid DM1 in Patients with Advanced or Metastatic Solid Tumors of Epithelial Origin**	Treatment	**START Midwest** Investigators	START Midwest (616) 954-5554
APG-115	***APG-115*** **: A Phase I Study of the Safety, Pharmacokinetic and Pharmacodynamic Properties of Orally Administered APG-115 in Patients with Advanced Solid Tumors or Lymphomas**	Treatment	**START Midwest** Investigators	START Midwest (616) 954-5556

Ascentage Pharma: 1252	***APG-1252-US-001:*** **Phase I, Study of the Safety, Pharmacokinetic and Pharmacodynamic Properties of Intravenously Administered APG-1252 in Patients with Small Cell Lung Cancer (SCLC) or Other Solid Tumors**	Treatment	**START Midwest** Investigators	START Midwest (616) 954-5556
Ascentage Pharma: 1387	***APG-1387-US-001*** **: A Phase I Study of the Safety, Pharmacokinetic and Pharmacodynamic Properties of Intravenously Administered APG-1387 as a Single Agent or in Combination with Systemic Anti-cancer Agents in Patients with Advanced Solid Tumors or Hematologic Malignancies**	Treatment	**START Midwest** Investigators	START Midwest (616) 954-5556
BeiGene USA	***BGB-290-103:*** **A Phase IB Study to Assess the Safety, Tolerability, and Clinical Activity of BGB-290 in Combination with Temozolomide (TMZ) in Subjects with Locally Advanced or Metastatic Solid Tumors**	Treatment	**START Midwest** Investigators	START Midwest (616) 954-5556
Bristol-Myers Squibb	***CA031002:*** **A Phase I/II First-in-human Study of BMS-986258 (anti TIM3) Alone and in Combination with Nivolumab in Advanced Malignant Tumors**	Treatment	**START Midwest** Investigators	START Midwest (616) 954-5556
COM701-Compugen	***CPG-01-001:*** **A Phase IA/IB Study of COM701 as Monotherapy and in Combination with an Anti-PD-1 Antibody in Subjects with Advanced Solid Tumors**	Treatment	**START Midwest** Investigators	START Midwest (616) 954-5556
COM902-Compugen	***CPG-02-101:*** **A Phase I Study of the Safety and Tolerability of COM902 in Subjects with Advanced Malignancies**	Treatment	**START Midwest** Investigators	START Midwest (616) 954-5556

Coordination Pharmaceuticals: 100	***CPI-CL18-001:*** **A Phase I, First in Human Study Evaluation the Safety, Tolerability, and Pharmacokinetics of CPI-100 via Intravenous Infusion in Patients with Advanced Solid Tumors**	Treatment	**START Midwest** Investigators	START Midwest (616) 954-5556
Coordination Pharmaceuticals: 200	***CPI-200CL01:*** **A Phase I, First in Human Study Evaluation the Safety, Tolerability, and Pharmacokinetics of CPI-200 via Intravenous Infusion in Patients with Advanced Solid Tumors**	Treatment	**START Midwest** Investigators	START Midwest (616) 954-5556
Exelixis	***XL092:*** **A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors**	Treatment	**START Midwest** Investigators	START Midwest (616) 954-5556
Ikena	***IK-175-001:*** **A Phase I, Open-Label, Dose-Escalation, and Expansion Study of IK-175, an Oral Aryl Hydrocarbon Receptor (AHR) Inhibitor in Patients with Locally Advanced or Metastatic Solid Tumors and Urothelial Carcinoma**	Treatment	**START Midwest** Investigators	START Midwest (616) 954-5556
InhibRx-105	***INBRX-105:*** **An Open-Label, Multicenter, First-in-human, Dose-Escalation Phase I Study of INBRX-105 in Subjects with Locally Advanced or Metastatic Solid Tumors, Hodgkin or Non-Hodgkin Lymphoma**	Treatment	**START Midwest** Investigators	START Midwest (616) 954-5556
InhibRx-106	***INBRX-106:*** **An Open-Label, Multicenter, First-in-human, Dose-Escalation, Phase I Study of INBRX-106 in Subjects with Locally Advanced or Metastatic Solid Tumors**	Treatment	**START Midwest** Investigators	START Midwest (616) 954-5556

InhibRx-109	***INBRX-109:* An Open-Label, Multicenter, First-in-human, Dose-Escalation, Phase I Study of INBRX-109 in Subjects with Locally Advanced or Metastatic Solid Tumors Including Sarcomas**	Treatment	**START Midwest** Investigators	START Midwest (616) 954-5556
Innovent	***IBI188:* A Phase IA Study Evaluating the Safety, Tolerability, and Initial Efficacy of Recombinant Human Anti-Cluster Differentiation Antigen 47 (CD47) Monoclonal Antibody Injection (IBI188) in Patients with Advanced Malignant Tumors and Lymphomas**	Treatment	**START Midwest** Investigators	START Midwest (616) 954-5556
Klus	***KL264-01:* A Phase I/II, First-in-human, Study of SKB264 in Patients with Locally Advanced Unresectable/Metastatic Solid Tumors who are Refractory to Available Standard Therapies**	Treatment	**START Midwest** Investigators	START Midwest (616) 954-5556
Expanded Access Loxo	***LOXO-RET-18037:* A Multicenter Expanded Access Program (EAP) for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors with Rearranged During Transfection (RET) Activation (LIBRETTO-201)**	Treatment	**START Midwest** Investigators	START Midwest (616) 954-5556
MacroGenics-018	***MGC018-01:* A Phase I/II, First-in-human, Open-Label, Dose-Escalation Study of MGC018 (Anti-B7-H3 Antibody Drug Conjugate) Alone and in Combination with MGA012 (Anti-PD-1 Antibody) in Patients with Advanced Solid Tumors**	Treatment	**START Midwest** Investigators	START Midwest (616) 954-5556
MacroGenics-019	***MGD019:* A Phase I, First-in-human, Open-Label, Dose-Escalation and Cohort Expansion Study of MGA019, a Bispecific DART Protein Binding PD-1 and CTLA-4 in Patients with Unresectable or Metastatic Neoplasms**	Treatment	**START Midwest** Investigators	START Midwest (616) 954-5556

Merck-5618	***MK-5618:*** **A Phase IB Multicenter Clinical Study of Selumetinib (MK-5618) in Combination with Pembrolizumab (MK-3475) in Participants with Advanced/Metastatic Solid Tumors**	Treatment	**START Midwest** Investigators	START Midwest (616) 954-5556
Merck-8353	***MK-8353-013:*** **A Phase IB Study to Evaluate the Safety and Tolerability of MK-8353 in Combination with Pembrolizumab in Patients with Advanced Malignancies**	Treatment	**START Midwest** Investigators	START Midwest (616) 954-5556
Odonate	***ODO-TE-S101:*** **An Open-label, Study of the Effect of Tesetaxel on the QTc Interval and the Effect of Food, Itraconazole, and Rifampin on Tesetaxel Pharmacokinetics in Patients with Advanced Solid Tumors**	Treatment	**START Midwest** Investigators	START Midwest (616) 954-5556
Symphogen	***Sym021-01:*** **A Phase I Open-Label, Multicenter Trial Investigating the Safety, Tolerability and Preliminary Antineoplastic Activity of Sym021 (Anti-PD-1) in Patients with Advanced Solid Tumor Malignancies or Lymphomas**	Treatment	**START Midwest** Investigators	START Midwest (616) 954-5556
Syros	***SY-5609-101:*** **A Phase I Study of SY-5609, an Oral, Selective CDK7 Inhibitor, in Adult Patients with Selected Advanced Solid Tumors**	Treatment	**START Midwest** Investigators	START Midwest (616) 954-5556
SCI-CD47-001	***HU5F9-G4*** **: First-in-human Phase I Dose-escalation Trial of HU5F9-G4 in Patients with Advanced Solid Malignancies**	Treatment	**START Midwest** Investigators	START Midwest (616) 954-5556

R3767-ONC-1613	***REGN3767*** **: A Phase I, Open-label, Dose-escalation and Cohort Expansion First-in-human, Study of the Safety, Tolerability, Activity, and Pharmacokinetics of REGN3767 (Anti-LAG-3 mAb) Administered Alone or in Combination with REGN2810 (Anti-PD-1-mAb) in Patients with Advanced Malignancies**	Treatment	**START Midwest** Investigators	START Midwest (616) 954-5556
CP-MGA012-01	***MGA012*** **: A Phase I Study of the Safety, Tolerability, and Pharmacokinetics of MGA012 in Patients with Advanced Solid Tumors**	Treatment	**START Midwest** Investigators	START Midwest (616) 954-5556
ASN003-101	***ASN003*** **: A Phase I, Open-label, Dose-finding, and Cohort Expansion Study of ASN003 in Subjects with Advanced Solid Tumors**	Treatment	**START Midwest** Investigators	START Midwest (616) 954-5556
5F9004	***Hu5F9-G4-Cetuximab*** **: A Phase Ib/II Trial of Hu5F9-G4 in Combination with Cetuximab in Patients with Solid Tumors and Advanced Colorectal Cancer**	Treatment	**START Midwest** Investigators	START Midwest (616) 954-5556
APX-CLN-0011	**A Phase I Study of APX3330 in Patients with Advanced Solid Tumors**	Treatment	**START Midwest** Investigators	START Midwest (616) 954-5556
CP-MGA271-03	***Macrogenics Protocol CP-MGA271-03:*** **A Phase 1, Open-Label, Dose Escalation Study of MGA271 in Combination with Pembrolizumab in Patients with B7-H3-Expressing Melanoma, Squamous Cell Cancer of the Head and Neck, Non-Small Cell Lung Cancer, Urothelial Cancer and Other B7-H3-Expressing Cancers**	Treatment	**START Midwest** Investigators	START Midwest (616) 954-5556

CPI-0209	**A Phase I/II Study of CPI-0209 Monotherapy in Combination with Other Therapy in Patients with Advanced Solid Tumors**	Treatment	**START Midwest** Investigators	START Midwest (616) 954-5556
Sym 021	**Sym 021: A Phase 1, Open-Label, Multicenter Trial investigating the Safety, Tolerability, and Preliminary Antineoplastic Activity of Sym021 (Anti-PD-1) as Monotherapy and in Combination with either Sym022 (Anti-LAG-3) or SYM023 (Anti-TIM-3) in Patients with Advanced Solid Tumor Malignancies or Lymphomas**	Treatment	**START Midwest** Investigators	START Midwest (616) 954-5556
eFT226	**A Phase I-II Dose-escalation and Cohort-expansion of Study of Intravenous Zotatifin (eFT226) in Subjects with Selected Advanced Solid Tumor Malignancies**	Treatment	**START Midwest** Investigators	START Midwest (616) 954-5556
	Phase 1/2A Dose Escalation, Finding and Expansion Study Evaluating Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Anti Tumor Activity of PF-07104091 as a Single Agent and In Combination Therapy	Treatment	**START Midwest** Investigators	START Midwest (616) 954-5556
EPZ-6438	**A Phase I, Open-label Multi-dose Two-Part Study to Characterize the Effects of a Strong CYP3A4 Inhibitor on the Steady-State Pharmacokinetics of Tazemetostat (EPZ-6438), and the Effects of a Strong CYP3A4 Inducer on the Steady-State Pharmacokinetics of Tazemetostat in Subjects with Advanced Malignancies**	Treatment	**START Midwest** Investigators	START Midwest (616) 954-5556
NEON-1	**An Open-Label Study of ALPN-202 in Subjects with Advanced Malignancies (NEON-1)**	Treatment	**START Midwest** Investigators	START Midwest (616) 954-5556

	A Phase 1 Multicenter Global First in Human Study of the CD73 Inhibitor LY3475070 as Monotherapy or in Combination with Pembrolizumab in Patients with Advanced Solid Malignancies	Treatment	**START Midwest** Investigators	START Midwest (616) 954-5556
COM902	**A Phase 1 Study of the Safety and Tolerability of COM902 in Subjects with Advanced Malignancies**	Treatment	**START Midwest** Investigators	START Midwest (616) 954-5556
eFT226	**A Phase 1-2 Dose-Escalation and Cohort-Expansion Study of Intravenous eFT226 in Subjects with Selected Advanced Solid Tumor Malignancies**	Treatment	**START Midwest** Investigators	START Midwest (616) 954-5556
JTX-8064	**Phase 1 First-in-Human (FIH) Study of Leukocyte Immunoglobulin- Like Receptor B2 (LILRB2) Inhibitor Monoclonal Antibody (mAb) JTX-8064, as Monotherapy and in Combination with a Programmed Cell Death Receptor-1 (PD-1) Inhibitor, in Adult Subjects with Advanced Refractory Solid Tumor Malignancies**	Treatment	**START Midwest** Investigators	START Midwest (616) 954-5556
LYT-200	**A Phase 1/2 Open-label, Multi-center Study of the Safety, Pharmacokinetics, and Anti-tumor Activity of LYT-200 Alone and in Combination with Chemotherapy or Anti-PD-1 in Patients with Metastatic Solid Tumors**	Treatment	**START Midwest** Investigators	START Midwest (616) 954-5556
ARRY-558	**A Phase 1, Open-Label, Multi-Center, Dose Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Anti-Tumor Activity of PF-07284892 (ARRY-558) as a Single Agent and in Combination Therapy in Participants with Advanced Solid Tumors**	Treatment	**START Midwest** Investigators	START Midwest (616) 954-5556

GEN 1046	**First-in-human, open-label, dose-escalation trial with expansion cohorts to evaluate safety of GEN1046 in subjects with malignant solid tumors**	Treatment	**START Midwest** Investigators	START Midwest (616) 954-5556